Role of Silent Mutations in KRAS -mutant Tumors

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2024 Dec 10

PMID 39654099

Authors

Jun Lu

Chao Zhou

Feng Pan

Hongyu Liu

Haohua Jiang

Hua Zhong

Baohui Han

Affiliations

Soon will be listed here.

Abstract

Silent mutations within the RAS gene have garnered increasing attention for their potential roles in tumorigenesis and therapeutic strategies. Kirsten-RAS ( KRAS ) mutations, predominantly oncogenic, are pivotal drivers in various cancers. While extensive research has elucidated the molecular mechanisms and biological consequences of active KRAS mutations, the functional significance of silent mutations remains relatively understudied. This review synthesizes current knowledge on KRAS silent mutations, highlighting their impact on cancer development. Silent mutations, which do not alter protein sequences but can affect RNA stability and translational efficiency, pose intriguing questions regarding their contribution to tumor biology. Understanding these mutations is crucial for comprehensively unraveling KRAS -driven oncogenesis and exploring novel therapeutic avenues. Moreover, investigations into the clinical implications of silent mutations in KRAS -mutant tumors suggest potential diagnostic and therapeutic strategies. Despite being in early stages, research on KRAS silent mutations holds promise for uncovering novel insights that could inform personalized cancer treatments. In conclusion, this review underscores the evolving landscape of KRAS silent mutations, advocating for further exploration to bridge fundamental biology with clinical applications in oncology.

References

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Kimchi-Sarfaty C, Oh J, Kim I, Sauna Z, Calcagno A, Ambudkar S . A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2006; 315(5811):525-8. DOI: 10.1126/science.1135308. View

. Pan-cancer analysis of whole genomes. Nature. 2020; 578(7793):82-93. PMC: 7025898. DOI: 10.1038/s41586-020-1969-6. View

Katti A, Diaz B, Caragine C, Sanjana N, Dow L . CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022; 22(5):259-279. DOI: 10.1038/s41568-022-00441-w. View

Linnane E, Davey P, Zhang P, Puri S, Edbrooke M, Chiarparin E . Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 2019; 47(9):4375-4392. PMC: 6511877. DOI: 10.1093/nar/gkz214. View

Subramaniam A, Pan T, Cluzel P . Environmental perturbations lift the degeneracy of the genetic code to regulate protein levels in bacteria. Proc Natl Acad Sci U S A. 2013; 110(6):2419-24. PMC: 3568297. DOI: 10.1073/pnas.1211077110. View

Kobayashi Y, Chhoeu C, Li J, Price K, Kiedrowski L, Hutchins J . Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022; 603(7900):335-342. DOI: 10.1038/s41586-022-04451-4. View

Plotkin J, Kudla G . Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet. 2010; 12(1):32-42. PMC: 3074964. DOI: 10.1038/nrg2899. View

Raponi M, Kralovicova J, Copson E, Divina P, Eccles D, Johnson P . Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Hum Mutat. 2011; 32(4):436-44. DOI: 10.1002/humu.21458. View

10.

Lampson B, Pershing N, Prinz J, Lacsina J, Marzluff W, Nicchitta C . Rare codons regulate KRas oncogenesis. Curr Biol. 2012; 23(1):70-5. PMC: 3567844. DOI: 10.1016/j.cub.2012.11.031. View

11.

Kranenburg O . The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005; 1756(2):81-2. DOI: 10.1016/j.bbcan.2005.10.001. View

12.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

13.

Junttila M, Karnezis A, Garcia D, Madriles F, Kortlever R, Rostker F . Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010; 468(7323):567-71. PMC: 3011233. DOI: 10.1038/nature09526. View

14.

Izar B, Zhou H, Heist R, Azzoli C, Muzikansky A, Scribner E . The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014; 9(9):1363-9. DOI: 10.1097/JTO.0000000000000266. View

15.

Hunter J, Manandhar A, Carrasco M, Gurbani D, Gondi S, Westover K . Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015; 13(9):1325-35. DOI: 10.1158/1541-7786.MCR-15-0203. View

16.

Young A, Lou D, McCormick F . Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2012; 3(1):112-23. DOI: 10.1158/2159-8290.CD-12-0231. View

17.

Buhr F, Jha S, Thommen M, Mittelstaet J, Kutz F, Schwalbe H . Synonymous Codons Direct Cotranslational Folding toward Different Protein Conformations. Mol Cell. 2016; 61(3):341-351. PMC: 4745992. DOI: 10.1016/j.molcel.2016.01.008. View

18.

Hunt R, Simhadri V, Iandoli M, Sauna Z, Kimchi-Sarfaty C . Exposing synonymous mutations. Trends Genet. 2014; 30(7):308-21. DOI: 10.1016/j.tig.2014.04.006. View

19.

Hia F, Yang S, Shichino Y, Yoshinaga M, Murakawa Y, Vandenbon A . Codon bias confers stability to human mRNAs. EMBO Rep. 2019; 20(11):e48220. PMC: 6831995. DOI: 10.15252/embr.201948220. View

20.

Fu J, Dang Y, Counter C, Liu Y . Codon usage regulates human KRAS expression at both transcriptional and translational levels. J Biol Chem. 2018; 293(46):17929-17940. PMC: 6240855. DOI: 10.1074/jbc.RA118.004908. View